JP2017538697A - 新規なアリール−シアノグアニジン化合物 - Google Patents

新規なアリール−シアノグアニジン化合物 Download PDF

Info

Publication number
JP2017538697A
JP2017538697A JP2017530168A JP2017530168A JP2017538697A JP 2017538697 A JP2017538697 A JP 2017538697A JP 2017530168 A JP2017530168 A JP 2017530168A JP 2017530168 A JP2017530168 A JP 2017530168A JP 2017538697 A JP2017538697 A JP 2017538697A
Authority
JP
Japan
Prior art keywords
dihydro
cyano
carbamimidoyl
dichlorophenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538697A5 (enExample
Inventor
モワット，ジェフリー・スチュアート
ステルフェルト，ティモ
シュトレーゼマン，カルロ
ヒリック，ロマーン
コール，ジルケ
ストッキヒト，デトレフ
ヴァイスケ，ヨルグ
ブランビー，トーマス
バラク，ナオミ
クリスト，クララ
ターラーク・アントニウス
バドック，フォルカー
クランプトン，ローズマリー・ヘレン
ステファヌティ，イアン
Original Assignee
バイエル ファーマ アクチエンゲゼルシャフト
バイエル ファーマ アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル ファーマ アクチエンゲゼルシャフト, バイエル ファーマ アクチエンゲゼルシャフト filed Critical バイエル ファーマ アクチエンゲゼルシャフト
Publication of JP2017538697A publication Critical patent/JP2017538697A/ja
Publication of JP2017538697A5 publication Critical patent/JP2017538697A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017530168A 2014-12-08 2015-12-08 新規なアリール−シアノグアニジン化合物 Pending JP2017538697A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14196766.1 2014-12-08
EP14196766 2014-12-08
EP15163993 2015-04-17
EP15163993.7 2015-04-17
PCT/EP2015/078912 WO2016091845A1 (en) 2014-12-08 2015-12-08 Novel aryl-cyanoguanidine compounds

Publications (2)

Publication Number Publication Date
JP2017538697A true JP2017538697A (ja) 2017-12-28
JP2017538697A5 JP2017538697A5 (enExample) 2019-01-24

Family

ID=54838348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530168A Pending JP2017538697A (ja) 2014-12-08 2015-12-08 新規なアリール−シアノグアニジン化合物

Country Status (7)

Country Link
US (1) US10023539B2 (enExample)
EP (1) EP3230274B1 (enExample)
JP (1) JP2017538697A (enExample)
CN (1) CN107207442A (enExample)
CA (1) CA2969771A1 (enExample)
ES (1) ES2722431T3 (enExample)
WO (1) WO2016091845A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN109778407B (zh) * 2019-02-18 2020-08-11 宁波荣昌祥服饰股份有限公司 一种抗菌面料及其制备方法
CA3137218A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3137611A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用
CN116327748B (zh) * 2023-04-21 2024-09-17 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007157A1 (de) * 2003-07-15 2005-01-27 Bayer Healthcare Ag Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen
WO2006072353A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Azetidin-substituierte pyrazoline als par-1 antagonisten
WO2006072350A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Cyanoguanidin-substituierte pyrazoline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE155129T1 (de) 1990-01-31 1997-07-15 Du Pont Pyrazolin-, pyrazolidin- und hydrazinderivate mit wirkung gegenüber arthropoden
DE102004061747A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophen-substituierte Pyrazoline
JP5881705B2 (ja) * 2010-09-03 2016-03-09 フォーマ ティーエム， エルエルシー． Ｎａｍｐｔの阻害のための新規化合物及び組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007157A1 (de) * 2003-07-15 2005-01-27 Bayer Healthcare Ag Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen
WO2006072353A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Azetidin-substituierte pyrazoline als par-1 antagonisten
WO2006072350A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Cyanoguanidin-substituierte pyrazoline

Also Published As

Publication number Publication date
US20170342034A1 (en) 2017-11-30
ES2722431T3 (es) 2019-08-12
EP3230274B1 (en) 2019-01-30
CN107207442A (zh) 2017-09-26
WO2016091845A1 (en) 2016-06-16
US10023539B2 (en) 2018-07-17
EP3230274A1 (en) 2017-10-18
CA2969771A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
EP3700904B1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
JP2017538697A (ja) 新規なアリール−シアノグアニジン化合物
JP6704398B2 (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
CN106715415B (zh) 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮
CN104125957A (zh) 取代的苄基吡唑
CN105408324A (zh) 取代的苄基吡唑
HK1222846A1 (zh) 取代的苄基吡唑
JP2016536311A (ja) ヘテロアリール置換ピラゾール類
US20240307362A1 (en) 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
CA2901267C (en) Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
US12403135B2 (en) 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2018104307A1 (en) Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
US20180118722A1 (en) Novel aryl-cyanoguanidine compounds
EP3259251A1 (en) N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
WO2024003259A1 (en) Tead inhibitors
US20180099937A1 (en) Novel aryl-cyanoguanidine compounds
HK1203196B (en) Substituted benzylpyrazoles
HK1226733A1 (en) Heteroaryl substituted pyrazoles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200324